Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prostate cancer screening: Decision-making when MRI results are inconclusive for cancer (PI-RADS 3).

Urologic oncology·2026
Same author

Adjusting for non-compliance and contamination with a more plausible assumption.

Journal of medical screening·2026
Same author

The efficient stored specimen design for evaluating multiple screening technologies: Application to multicancer detection tests.

Journal of medical screening·2025
Same author

Minimum test tradeoff applied to uterine artery pulsatility index for antepartum prediction of preeclampsia.

Pregnancy hypertension·2025
Same author

Trends in use of the new MeSH term "overdiagnosis": A bibliometric review.

Health information and libraries journal·2025
Same author

False premises, false promises: celebrity endorsement of non-evidence-based anticancer interventions on social media.

Health promotion international·2025
Same journal

Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE.

Journal of the National Cancer Institute·2026
Same journal

Beyond R2: Assessing quality of trial level surrogate endpoints in colorectal cancer.

Journal of the National Cancer Institute·2026
Same journal

A novel classification of small bowel adenocarcinoma based on the hidden genome classifier: a multi-institutional study.

Journal of the National Cancer Institute·2026
Same journal

Response to Yu, Wang and Ge.

Journal of the National Cancer Institute·2026
Same journal

Re: Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphoma.

Journal of the National Cancer Institute·2026
Same journal

Welcome reduction of US cervical cancer rates despite state differences.

Journal of the National Cancer Institute·2026
See all related articles

Related Experiment Video

Updated: May 15, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Surrogate endpoint analysis: an exercise in extrapolation.

Stuart G Baker1, Barnett S Kramer

  • 1National Cancer Institute, EPN 3131, 6130 Executive Blvd, MSC 7354, Bethesda, MD 20892-7354, USA. sb16i@nih.gov

Journal of the National Cancer Institute
|December 25, 2012
PubMed
Summary
This summary is machine-generated.

Surrogate endpoints in cancer trials can shorten studies but risk misleading results due to extrapolation. Careful validation is crucial for reliable cancer research using these endpoints.

Related Experiment Videos

Last Updated: May 15, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Area of Science:

  • Oncology
  • Biostatistics
  • Clinical Trial Design

Background:

  • Surrogate endpoints offer potential for more efficient cancer clinical trials.
  • However, their use involves extrapolation, which can lead to inaccurate conclusions.
  • The validity of surrogate endpoints relies on specific statistical criteria.

Purpose of the Study:

  • To analyze the challenges and risks associated with using surrogate endpoints in cancer research.
  • To highlight the critical importance of understanding extrapolation in surrogate endpoint trials.
  • To examine the implications for both cancer prevention and treatment studies.

Main Methods:

  • Examined the sensitivity of small surrogate endpoint trials in cancer prevention to deviations from the Prentice criterion.
  • Investigated estimation extrapolation in cancer treatment trials using historical data.
  • Calculated a standard error multiplier to quantify uncertainty in prediction using surrogate endpoints.

Main Results:

  • Small surrogate endpoint trials for cancer prevention are highly sensitive to violations of key statistical criteria.
  • Extrapolation for treatment effect estimation introduces increased uncertainty, quantified by a standard error multiplier.
  • Additional factors like biological mechanisms and side effects must be considered post-extrapolation.

Conclusions:

  • Surrogate endpoints in cancer research necessitate a thorough understanding of extrapolation challenges.
  • Misleading conclusions are a significant risk if extrapolation issues are not adequately addressed.
  • Careful consideration of statistical assumptions and potential biases is paramount for valid surrogate endpoint use.